EL.En. S.p.A. (ELN) Earnings Call Transcript & Summary

May 16, 2022

Borsa Italiana IT Health Care Health Care Equipment and Supplies earnings 63 min

Earnings Call Speaker Segments

Operator

operator
#1

Alright, good afternoon everyone, and thanks for joining El.En.'s conference call covering the Q1 2022 financial results. This call is being recorded today, and at the end of it there will be a chance to ask questions. Joining me are Andrea Cangioli, El.En.'s CEO, and Enrico Romagnoli, El.En.'s CFO and Investor Relations. Before we get started, please be aware that management will make remarks on this conference call regarding future expectations, plans and prospects, as well as forward-looking statements. Some statements during this call — including those dealing with the company's beliefs, plans, objectives, estimates or expectations of possible future results or events — are forward-looking statements. Such statements carry known or unknown risks, among them general economic and business conditions and conditions in the industry we operate in, and they may be affected if our assumptions prove inaccurate. As a result, no forward-looking statement can be guaranteed, and actual future results, performance or achievements could differ materially from those expressed or implied by such forward-looking statements. The company assumes no obligation regarding the contents, nor to update the forward-looking statements to reflect events or circumstances that may arise after the date hereof. If you would like to ask a question, please book your questions on the chat of Bianca Fersini Mastelloni, and she will be happy to introduce you following the booking order.

Operator

operator
#2

I’ll now hand things over to Andrea Cangioli. Andrea, the floor is yours.

Andrea Cangioli

executive
#3

Thanks, Nicola, and thanks to all of you for being on this call, which El.En. is hosting following the publication of the financial report for the first quarter of 2022. Joining me on the line is Enrico Romagnoli, who in a few minutes will take you through the details of our financial results. In a few seconds, actually. As you may have gathered from our press release, the first quarter was again a very strong one, with demand that remained sustained, letting us post excellent results in revenues, EBIT and EBIT margin, with each of them at record levels for the specific quarter, which is seasonally the weakest in our capital goods market. Just to give a summary before going into the details, revenues rose 24% to EUR 144 million, while EBIT came in at EUR 17 million, 11.8% on revenue. This last EBIT margin is perhaps the most remarkable among the remarkable achievements of this quarter, surpassing Q1 2021 and also the average 2021 margin as well. Enrico, please go ahead with the financial reporting section.

Enrico Romagnoli

executive
#4

Thank you, Andrea. As Andrea mentioned, Q1 of 2022 delivered a record result, with consolidated revenue of EUR 144 million, up 24%, and double-digit growth in both main areas of activity, medical and industrial. The EBIT margin came in at 11.8%, a brilliant result for the first quarter, which is seasonally the weakest of the year, thanks to the great growth in sales volume. In 2022, we saw an improvement in terms of gross margin, mainly due to an impact of medical sales higher than industrial on the total turnover, and the profitability in terms of gross margin of medical sector is higher than industrial. The strengthening of the U.S. dollar, together with the increase in turnover in dollars to North America, improvement of margin in industrial sector. Thanks to the improvement of gross margin and the stability of the impact of fixed cost on sales, EBITDA was positive for EUR 20.1 million, an increase of approximately 29% compared to the EUR 15.6 million in Q1 2021. EBITDA margin in the first quarter 2022 was equal to 13.9%, exceeding the EBITDA margin of the first quarter 2021 that was equal to 13.4%. In the same time, EBIT for the quarter showed a positive balance of EUR 17.1 million, up by 32% compared to the 12.9 million in the Q1 2021.

Enrico Romagnoli

executive
#5

The impact of the operating result on sales comes to 11.8%, up from 11.1% in the first quarter of 2021. Ultimately, EBIT — EBT — showed a positive balance of roughly EUR 17.5 million, a significant rise of 24.4% versus the EUR 14.1 million posted in Q1 2021. The net financial position stood positive at EUR 85.8 million, against EUR 150.7 million as of December last year, a reduction of EUR 30 million. On this chart, you can see the group produced cash from operating activities, while net working capital expansion aimed at supporting stable production processes absorbed around EUR 36 million — over EUR 23 million of that from higher inventories, and about EUR 13 million from a decrease in trade payables. Also, note that fixed asset investments surpassed EUR 4 million during the quarter. Looking at the breakdown by business, the medical sector posted growth of roughly 30% versus the same period in 2021. Although it had the sector's lowest growth rate, the aesthetic segment's performance was very satisfactory thanks to the product mix sold. Indeed, sales of the small home-use system distributed by Japan fell significantly in the quarter.

Enrico Romagnoli

executive
#6

We did see a huge rise in sales volume for our high power laser used in hair removal, and that came with strong profitability for the group. One thing that stood out in percentage terms was how strongly the surgical system bounced back, since it had been having a hard time shaking off the pandemic-driven sales downturn. Turning to service revenue, the increase in turnover came mainly from optical fibers for surgical use in urology; production there had taken a sharp hit early in 2021 because of some technical production issues, which were resolved over the months that followed. The industrial sector posted a 16.4% rise in turnover versus the first quarter of 2021. Revenue growth, which confirms the positive trend of recent years, showed gains of between 8% and 21% in nearly every segment, apart from marking. The cutting sector grew more strongly, up 21%, with turnover of EUR 47.4 million, while results in China were only just satisfactory, affected by the recent round of lockdowns. Meanwhile, the growth Cutlite Penta delivered in Italian and European markets was very strong. Marking saw a 13.3% decrease versus the first quarter of 2021, with sales of EUR 4.4 million, a drop we hope to make up over the remainder of the year.

Enrico Romagnoli

executive
#7

We saw gains in the other two segments as well — laser sources and services. Geographically speaking, performance was strong across every region and every segment where we operate. The medical sector's sales were particularly notable in Europe, up 49%, helped by a favorable trend in aesthetic system sales, and in the rest of the world, up 26%. That was driven mainly by sales to the United States of America, and this held despite the negative phase in Japan — both because of prolonged pandemic restrictions and because of the weakening sales cycle for small home use devices that marked the last two years. In the industrial sector, the highest growth rate came in Italy, where a 28% increase was recorded, and the largest part of that growth was delivered by Cutlite Penta in the metal cutting sector. Andrea, you can go ahead for the presentation.

Andrea Cangioli

executive
#8

All right. I’ll go on and give you a bit more color on what’s happening and what has been happening. We’re clearly very happy with these results. A few key drivers explain this excellent outcome. Demand was strong, and we keep gaining from a large backlog in our order books. We had anticipated robust demand in our market segments based on how we read market developments—confirmed by market studies where available—and our expectations were broadly met. Given those expectations, we put financial and managerial resources into strengthening our infrastructure so we could capture the opportunities the markets were offering and will offer. I’m referring to the new capacity expansions involving our Chinese activities, Quanta in Samarate, ASA in Vicenza, Lasit in Torre Annunziata, Cutlite Penta in Prato as well, and last but not least, here in Calenzano. By the way, we’re glad to be able once more to host an investor day here in Calenzano, at our premises, to show directly to those of you who can join us on the 31st how our floor organization has changed here in Florence and how important the new Prato plant is for the sheet metal cutting business.

Andrea Cangioli

executive
#9

So, turning back to how we've been strengthening our structure — that involved not just bricks, devices, and tools, but also, and most importantly, people. We added more people in R&D, technical experts, wizards in several circumstances so we can innovate, and compliance experts so we can expand the areas where our products can actually be sold. We also put people and marketing efforts behind supporting our distribution networks, both where we go direct — as we do in Italy, Germany, France, and Japan — and in all the other countries where we partner with top-level local distributors. So our markets are positive, they're growing, and they're in a very positive phase. A great deal of preventive work has been put in place so that we could follow and beat the market over these last quarters. If the markets and our backlogs look extremely helpful — and they are — the same does not apply to several other general circumstances we need to face in this 2022. The list is short but dense. The Russian invasion of Ukraine and its consequences, first of all, the worsening of the already strong inflation. The continued struggling of several of our suppliers, who are not able to timely react to our demand increase needs and very often are not even able to comply to our current commitments.

Andrea Cangioli

executive
#10

The lockdowns in China have, over the last months, made things harder for our business and for any business in that territory, since they enforced reduced mobility — not only in the way we were accustomed to, from and to China, which remains a huge constraint on relations with China, but now also inside the provinces, which has been putting at risk the growth we expected in the domestic consumption market as well. Let me start from that last point: China matters quite a lot to us, particularly in metal cutting, where we have a fairly large organization, with our factories in Wuhan, Guangzhou, and Linyi. Unlike the lockdowns of early 2020, our production sites faced no restrictive injunction and were permitted to operate normally. That doesn't mean conditions were normal, because lockdowns were striking other major areas here and there, such as Ningbo and then Shenzhen, and then up to Shanghai and Beijing. Sales activity couldn't be carried out as ordinary, and likewise delivery, installation, and the clearing of orders — which comes with successful final testing at the customer — couldn't be done as usual. The upshot was a decent quarter for the Chinese sheet metal cutting business, with revenues in renminbi just below the very good Q1 2021 quarter.

Andrea Cangioli

executive
#11

Because the structure grew larger and more expensive, income came in lower. The downside is that we had anticipated stronger performance, and lockdowns continue to weigh on our results in a quarter — the second — when we had looked for very strong figures. The upside is that within our own market segment we are performing quite well. We have, so to speak, a COVID-related environmental problem still affecting international relations and travel both from and to China, and now once more affecting daily life in mainland China, which is slowing the entire economy. Conversely, the sales mix proved highly favorable, with growing weight in high power laser systems — a segment where our superior capability to effectively manage 20 and 30-kW laser beams is enabling a better margin on sales and a very interesting market outlook across application segments that only such laser power can effectively address, namely laser cutting system. The second issue of these times, and perhaps the most concerning, is the war. The definite effects of the war on our business so far are the loss of the Russian and Ukrainian markets and the rise in energy cost, which in turn is producing a strong inflation impact.

Andrea Cangioli

executive
#12

On top of that, with the war so near to us, Europe and the world are left in a state of significant uncertainty. As with other conflicts occurring farther away, we have so far observed no direct effect on our markets, and demand has remained largely unaffected, with customers keeping their confidence and continuing to invest in our products. Since the war's developments are uncertain, the real and psychological consequences of any turn in the war cannot be predicted. Inflation is the concrete effect on our business, pushing us into a new situation, or at least one we had not encountered for years. Energy costs hit our operational expense directly, but it is in the cost of goods sold that the strongest impact shows up, with current component purchasing seeing average increases in line with official inflation rates, therefore well above 5%. Historically, raising prices on a given product has not served as a marketing tool for the group. Over a product's life cycle, prices have tended to fall, while price adjustments reached customers only when new products were released. Laser systems featuring new and improved capabilities can easily absorb price increases even in a world without inflation.

Andrea Cangioli

executive
#13

So at this point, raising prices across every product line becomes unavoidable if we want to avoid watching our margins get eaten away. Over the past several months, the supply chain has been the single biggest challenge we've faced. The count and the range of parts appearing in our shortage forecasts just keep growing. We had hoped and expected that 2022 would put an end to these shortages, yet the reality is that things are not getting better. The obvious impact you can see in our financials is the enormous buildup in raw material inventories. What doesn't show up in our financials, and what isn't obvious, is the constant work required to build production schedules we can actually meet given the materials that truly arrive, which frequently diverge sharply from the orders we placed and from the delivery plans our own suppliers give us. The worst production slowdown caused by shortages hit our Asclepion plant during March and April. Output of MeDioStar devices dropped substantially, and that also had an effect on Esthelogue, the Italian distributor for the MelaStar. Even with this very large problem at the Asclepion production facility, it still managed to grow its revenue by 19% in the quarter.

Andrea Cangioli

executive
#14

With this profile, our aim is to avoid shortages, so we place volume orders for the production volumes we expect and sometimes want, and given the solid backlog those are fairly large. Normally, manufacturing gets most of the materials it needs on time, yet for a very small number of components we come up short by a short percentage in value — parts that are still essential to manufacturing — and that slows the production pace and raises our raw material reserve, which covers most of the needs of the production volumes we cannot achieve. At this stage it is also impossible, or at least not advisable, to slow the purchasing pace with our vendors, who could choose or could be compelled to cut their volumes or divert their production volumes. We must stick to what we have ordered. That is the mechanism behind the inventory increase, which is quite interesting, because in a 24% growth order I actually attribute most of the inventory increase to product, to production volumes that came in below expectations. Having spent so much time on the problems bothering us right now, I would also like to stress how effectively our functions are committed to overcoming the operational problems that appear every day in an unprecedented fashion, and how effective they have been, as our quarterly results show.

Andrea Cangioli

executive
#15

Our optimism about how the business will perform through the remainder of the year remains strong, and at this point I want to highlight a few of the encouraging items in our quarterly financials. I'm simply underlining certain remarks Enrico made earlier. Despite a very challenging situation in China, revenues at the laser cutting division rose 19% and the division turned a profit during the quarter. Profitability came in below expectations in Q1 2022, largely because of contingent aggressive sales policies in Italy, which should carry less weight over the coming months. Surgery revenue was material once more, putting this business back onto the growth trajectory we had set out for it before the pandemic. Alongside the material, almost 40% increase in system revenue, we benefit from attached sales of the consumables used with the urological device, namely the optical fibers Enrico referred to earlier. The therapy business posted the same robust rebound, with ASA returning to its excellent rates of growth and profitability. In hair removal, our market position is growing progressively stronger. Our product range, which includes a broad selection of systems for differing pockets and workloads, is impressive.

Andrea Cangioli

executive
#16

When it comes to high power Alexandrite lasers, there's DEKA's Again — which just picked up an award at Monaco's International Anti-Aging Conference — along with Quanta System's Thunder, and the Elite+, the system El.En. builds for the Cynosure brand. That one adds to Cynosure's brand sales around the world, and it adds to our own sales and production volume as well. On the medium power side, we have the Motus and the Duetto, both Alexandrite laser systems. The top-selling system remains the MeDioStar, the German technology semiconductor device made in Asclepion, Jena. How well this outstanding product range is performing shows clearly in the solid revenue growth of the aesthetic segment. As for the single segment where the minus sign appeared in the revenue comparison chart — I'm talking about laser marking — the business outlook is more than positive, and it is overcoming the production obstacles left over from COVID in our manufacturing during the first months of the year. We also expect to benefit from the good work of our new sales subsidiary for Laser Marking systems, which was set up in Poland at the end of last year and is now starting to consolidate. So, wrapping up, before I leave this meeting to your questions, I'd like to summarize the overall outlook. What I mean is, the first quarter results were in line with the annual guidance.

Andrea Cangioli

executive
#17

What I mean is that they came in significantly higher than the 10% minimum revenue growth we had been signaling. EBIT was up compared with 2021. As I mentioned, we remain very optimistic about the remainder of the year, grounded first and foremost in the very strong order backlog and the order bookings recorded during the quarter. Our ambitions point to yet another record year on both revenues and profitability. When it comes to putting numbers on those targets, in light of the present degree of uncertainty and the threats to business as usual posed by the war and the lockdowns in China, we are reaffirming the current guidance: revenue growth above 10% and EBIT growth over 2022. Historically, we have raised guidance as the year progressed, and there are solid factors within our own business and our markets that argue for an adjustment this year as well. The uncertainties that lie just ahead suggest we should hold off on any upgrade, should one materialize, until closer to year-end. That concludes my presentation. Thank you for listening to it, and at this point please go ahead with your questions.

Bianca Fersini-Mastelloni

executive
#18

Andrea, the first question comes from Andrea Bonfà at Banca Akros. Please go ahead, Andrea.

Andrea Bonfà

analyst
#19

Hi there. Good afternoon, everyone. I hope my voice is coming through loud and clear. Can you hear me okay?

Andrea Cangioli

executive
#20

Yes.

Andrea Bonfà

analyst
#21

All right, good. Andrea, to start, congratulations on these results — truly exceptional. My first question is about the guidance once more. I realize this is a rather fine, shall we say, line or difference. Reading your press release and how you phrased things, you said at least 10% at year-end, yet in the first quarter you said well and above 10%. At least in terms of volume, that's an upgrade. If you could comment on that, at least. The second one concerns where your net cash position is headed. I mean, in your PR you stated that net cash fell because net working capital rose by roughly EUR 30-something million. I'm curious whether you can elaborate on the piece tied to stocks, which you said was EUR 24, EUR 25 or EUR 26 million. Is that tied to finished products, or to, let's say, buying more components so as to cope with the scarcity that's going on? Again, if you could elaborate on that. On that same point, whether the level of advances from your client is roughly the same as at year-end. Or has it now come down.

Andrea Bonfà

analyst
#22

Let me just make sure I understand how the net cash is structured. If you can, on urology — let's take a look. I mean, given the really strong consumable results, could you give us a sense of how large that business is on an annual basis, taking into account both the machines and the consumable? That would help us with our sum-of-the-parts work. And the last one, if I may, is China. You said that even though your number went up in absolute terms, you weren't happy with how you performed. Is all of that tied to COVID issues, or is there something else you'd like to flag for us or share? And would it be right to assume things are improving from Q2 in China? Thank you.

Andrea Cangioli

executive
#23

Turning to the guidance now. Yes, at some point we wrote “well above.” Clearly, when you post 24% revenue growth for the quarter and your guidance states more than 10%, you are above it — and well above it, too. What I can tell you is that if “well above” appears somewhere in writing, that reflects what we genuinely believe. As for the guidance, we are, as I mentioned, extremely optimistic, and we are delivering well above 10%. We are aiming well above 10%. The rationale for keeping the guidance unchanged is, first of all, that the second half of 2021 was very brilliant, so the comparison base will be tougher. That is not really the reason we stay prudent, or the main reason we stay prudent. The main reason we stay prudent is what I covered in a lot of detail during my presentation. There are certain situations in which we can keep operating normally. I am referring to the impact of the war, the impact of the lockdowns and the impact of the shortages. These three problems could, quite unpredictably and unexpectedly, become much harsher. Although we are optimistic by nature, the imminence of events beyond our control leads us to keep a guidance that remains open.

Andrea Cangioli

executive
#24

I mean, better results could come from it, but today we don't want to make a change. If we find that we keep navigating these waters successfully for additional months, then we'll update it at that point. That doesn't mean we're intimately optimistic about our business conduct, but we also have to take into account the kind of environment we're working in. The second question concerned the net financial position and the inventory. Enrico can provide the exact details here. Roughly, I believe, inventory is up by EUR 26 million, accounts payable are down by about EUR 10 million, and receivables are up by about EUR 2 million. Enrico, am I wrong? Enrico?

Bianca Fersini-Mastelloni

executive
#25

Enrico,

Enrico Romagnoli

executive
#26

Sorry to jump in. Inventory rose by EUR 23 million, and raw material accounted for the bulk of that, at EUR 15 million. As for the down payment we received from the customer, it's roughly at the same level as at year-end. There's a small increase of a couple of EUR 2 million.

Andrea Cangioli

executive
#27

What we're doing and what's going on is answered by my earlier remarks. We are buying. To put it plainly, we intend to produce a set amount, and we buy for that amount. The situation is that we can't produce that level of volume, since the goods we order arrive only in part. So this has been going on for several months running. We don't risk halting purchases, because under these conditions, with our suppliers under strain, if we were to stop buying from them, they might choose to cut off our material supply. So we even choose to keep investing. We perceive no material risk in putting money into materials so as to have everything lined up to produce effectively in the months ahead. The other question concerned urology. We have never revealed the actual figures for urology, but, well, since there's a fairly big number of people — urology sales of boxes in Q1 2022 came to more than EUR 10 million. Consumables sales in urology — fibers, that is — this quarter, a record quarter, and likely to stay a record quarter for a long time given some exceptional volumes, came close to EUR 10 million.

Andrea Cangioli

executive
#28

So, looking at the quarter overall—consumables plus boxes included—we came in just under EUR 20 million. And naturally, on this chart you can see EUR 14.5 million in surgical, which covers systems, but that figure also takes in systems for other applications such as ear, nose and throat, gynecology, and a modest slice of veterinary surgery that we record under surgery. On the China question, you noted that I wasn't happy with China. How could anyone feel happy about a sales performance that lockdowns once again hit so hard? We were aware we'd face a tough comparison against 2021 during the first half of 2022, since the first half of 2021 had been an extremely strong post-COVID rebound in China. Beyond that demanding benchmark, we also ran into an unfavorable environment. From that standpoint, the China results were, of course, disappointing—and I say disappointing because of this situation. As I noted, within that disappointment—since circumstances drove us to this result—there is very positive news that once more confirms we have something to offer in this market thanks to our specific positioning. That specific positioning is precisely what let us, in a quarter with clear headwinds in the Chinese market, raise the average prices of our sales and lift the margin on sales, given that we are expanding into market segments that are more rewarding.

Andrea Cangioli

executive
#29

Right now we hold an edge over rivals in those more lucrative market segments. Had we been unable to deliver on the ground, or unable to actually get systems installed across several provinces of China, that clearly hurt how we did — and judged purely by the numbers, the result wasn't very satisfactory, yet it was a good performance, and in fact a very good one when you set it against the circumstances.

Andrea Bonfà

analyst
#30

That's great. Thanks a lot, Andrea.

Andrea Cangioli

executive
#31

No problem at all.

Bianca Fersini-Mastelloni

executive
#32

Andrea, there’s a further question coming from François Robillard at Intermonte. François, please go ahead.

François Robillard

analyst
#33

Hello, everyone. Good afternoon, and thanks for taking my question. My first one concerns the margin guidance. If I heard you right in your prepared remarks, you said you were anticipating a record year where profitability is concerned. Is there anything we should read into that regarding the percentage of margin, or are you staying with only the quantitative indication you provided of EBIT growth in absolute value? My second question relates to the FX impact in the first quarter. Essentially, with the U.S. dollar appreciating against the euro, what kind of effect did that have on your performance in Q1, both on top line and on the EBITDA margin contribution? The third question, which is somewhat related, concerns your expectation going forward for the U.S. market. Some of your peers have offered some fairly bullish expectations. What do you expect for this market, and how do you plan to address this strong local demand? Finally, on fixed costs, if my calculations are right, you had roughly EUR 35 million between staff costs and other operating costs in the first quarter. Can we expect something more in the coming quarters, especially since in the past you mentioned returning to trade fairs and other events, and the effort you made on staff — what kind of floor quarterly spend can we expect looking at those cost lines?

François Robillard

analyst
#34

I appreciate that.

Andrea Cangioli

executive
#35

Alright. Thanks, François. Now, to the question — when I say we expect record profitability, record profits, that's simply in line with the guidance. If we achieve 10% growth over a record year, revenue will be at a record. If EBIT improves compared with a record year, EBIT will be at a record. Regarding guidance, I think I already covered our position at length when I responded to Andrea Bonfà. There's nothing further I can add. On foreign exchange, we worked out that the net overall impact of FX on revenues — after both increases and decreases — came to 3.6% this quarter. 3.6% this quarter. It was naturally larger in the U.S. dollar segment, since there was an adverse effect from the Japanese yen, which matters quite a lot for us. What this means is that, on dollar sales right now, we're enjoying a fairly significant advantage, probably around 10%, in terms of the value of the sale. Then, naturally, we have to bear in mind that significant purchases are made in the U.S. in U.S. dollars. So that 10% advantage doesn't translate entirely into margin, because we also see cost of goods sold rising.

Andrea Cangioli

executive
#36

When you look at the medical segment overall, that's the part where we bill in U.S. dollars, the gross margin there did not go up compared with the gross margin in the last quarter of 2021. The reason was a margin benefit from foreign exchange on sales, offset also by higher cost from two things. First, OEM sales rose, and those carry a lower gross margin, though they come with bigger volumes, so they produce an advantage at EBIT level even if we give up a little on gross margin, and second, there was also a cost increase. We aren't disclosing any detail, any further detail here regarding the foreign exchange effects. What I can say is that as the U.S. dollar strengthens, we expect margin on U.S. dollar sales to keep rising, obviously, and we're counting on that effect to offset both the cost increase in the U.S. dollar component and the cost increase that comes from general inflation. We don't model a great impact, an overall impact on margin, as the net effect of all the positive and negative components.

Andrea Cangioli

executive
#37

I want to point out that our product mix heavily affects total margins. The reason is that when you sell more in segments with thin margins, such as industrial, or when you sell more of certain products inside particular segments that carry lower margins — OEM hair removal laser systems, just to give one example — that pushes margins down further. Conversely, when you sell more in other segments, such as surgery, where margins are good, margins will rise. It's very hard to build any model around pricing and around actual margins, given — I mean — how extremely turbulent the whole environment is. Did that cover everything you asked, François?

François Robillard

analyst
#38

No. Only regarding fixed costs.

Andrea Cangioli

executive
#39

Yeah.

François Robillard

analyst
#40

Could you revisit the first-quarter increase and share what we should expect going forward?

Andrea Cangioli

executive
#41

We aren't giving out any information, any detailed information about this. What I can say is that, if you noticed, there was an increase in the impact of operational expenses on revenue. That increase comes from several different accounts, but mainly from one, which is the return of traveling and the return of trade fairs. The answer, if we expect a higher cost for these two accounts, the answer is yes. We expect a slow increase in the operational expense for international traveling and international sales and congresses, which obviously were not taking place at all. We also expect, as operational expense, an increase due to energy costs. Even though energy costs are not impacting our cost of goods sold directly, they are impacting our expense. Among the single accounts that were adding up to the increase of our operational expenses, the lines related to heating, we were in the winter, were the most affected. Of course, we expect, therefore, a growth in operational expense. Difficult to quantify. We expect to be able to grow even more rapidly our sales volume and to offset the extra cost, leading to an increase in EBIT.

François Robillard

analyst
#42

Thanks.

Bianca Fersini-Mastelloni

executive
#43

Andrea, there’s one final question coming from Hugo Mas at Sycomore Asset Management. Hugo, go ahead.

Hugo Mas

analyst
#44

Yes. Hi there, Andrea.

Andrea Cangioli

executive
#45

Hello there.

Hugo Mas

analyst
#46

My questions are mostly about China. Could you help us gauge what sort of performance you delivered during April and the start of May in terms of sales growth or decline, just so we have a sense of what the lockdowns in China might be causing right now? The second question concerns the IPO of the China due to laser cutting. Have you made any progress in that area?

Andrea Cangioli

executive
#47

Regarding your first question, we never provide detailed sales performance figures for the current period. What I can say is that in April, conditions are still having a negative effect on our business. There is some positive news. It appears Shanghai is opening up, yet the situation remains short of what we had hoped for during this period. Results falling below expectations of this kind also affect the potential for an IPO on the mainland China market. Naturally, because those sorts of financial solutions in China require the company to be performing very well—or at least, to be able to aspire to such a solution and to aspire to a good outcome in an IPO, we need to perform well. Given that we were underperforming in the quarter, it naturally becomes harder to pursue that kind of potential solution. Whereas we were unsure and merely pointing to the possibility of a potential IPO, today I confirm that a possibility of a potential IPO exists. Naturally, the better our performance, the more consistent the chances are of being able to, let's say, undertake a path toward an IPO.

Hugo Mas

analyst
#48

All right, that's great. Thanks a lot.

Bianca Fersini-Mastelloni

executive
#49

We’ve got a question from Paolo Cipriani at CP Capital. Paolo, go ahead. Thanks.

Paolo Cipriani

analyst
#50

Good afternoon. Maybe I could ask a couple if that's alright. To start with, I wanted to touch on the order backlog and the bookings. Would you be able to share a bit more detail on those? How are things shaping up right now?

Andrea Cangioli

executive
#51

Yes. That's yet another figure we address qualitatively. We've never given out numbers, since the order backlog always carries some level of uncertainty. Our preference is to avoid providing figures. What I can say is that we came into 2022 with record booking levels across every one of our segments. Medical, industrial, and that was also borne out — there was accounting evidence in the form of the huge volume of down payments recorded in our financial reports. Customers who had paid a certain percentage of their order to ensure delivery on time. Over these months, we had, for example, to clean out the order book of all the Russian and Ukrainian orders, which matters significantly in certain market segments. We managed to keep booking a significant number of orders. Just as an indicator — although not all orders carry down payments, the down payment indicator doesn't necessarily reflect the actual order backlog 100%. The total amount of down payments at the close of the first quarter was not materially different from the same amount booked at the end of the year.

Andrea Cangioli

executive
#52

So that means, let's say, you could infer a book-to-bill ratio of 1.

Paolo Cipriani

analyst
#53

Alright, understood. This is one more follow-up regarding margin. I mean, you laid out what conditions are like right now, but looking at this quarter, essentially the EBITDA margin has risen somewhat. It climbed to 30.9% versus 13.4% a year earlier. With energy and raw material inflation the way it is, I mean, could you perhaps walk me through once more how you've managed this situation and actually made the margin better when costs are in fact going up considerably.

Andrea Cangioli

executive
#54

I’m not sure I follow. I mean, when it comes to gross margin, mix is a factor. Mix always has to be taken into account. Looking at the overall mix, if we sold more in medical and industrial, that shifts the mix and shifts the margin. What I can say about our cost is that the cost increase goes back a long way. We began sourcing in the second half of 2021. Throughout all of 2021, we kept buying at very favorable prices thanks to the higher volumes, and so our cost of goods sold actually went down during 2021, even as the price increases were beginning to spread out. Now, in 2022, we’re starting to see material cost increases, but I mean, they’re averaging out against our 2021 costs, and they still aren’t having that much impact. We’ll see the cost of goods rise more and more as the year goes on. We also have other circumstances that let us offset the increase in cost of goods sold, such as the strong performance of the U.S. dollar against the euro, which allowed us to raise actual gross margins compared with the prior year. Lastly, if we look at overall margins, we are producing higher volumes of production.

Andrea Cangioli

executive
#55

Operating leverage is at work here, and that's exactly why our EBITDA unit margins are getting better.

Paolo Cipriani

analyst
#56

Alright. Thanks.

Bianca Fersini-Mastelloni

executive
#57

Andrea is here with me, and I don’t have any further questions.

Andrea Cangioli

executive
#58

Pardon me, but I notice a couple of hands raised.

Bianca Fersini-Mastelloni

executive
#59

Pardon me?

Andrea Cangioli

executive
#60

Yeah, I notice two hands raised. Gloria Ribeiro is one of them, with her hand up.

Analyst

analyst
#61

Emmanuel here.

Andrea Cangioli

executive
#62

That's not Gloria.

Bianca Fersini-Mastelloni

executive
#63

My apologies. My apologies, Emmanuel. Go ahead, Emmanuel. Emmanuel, go.

Analyst

analyst
#64

Good afternoon. I have just three questions for you.

Andrea Cangioli

executive
#65

Hello, this is Emmanuel speaking. Hey there. Pardon me.

Analyst

analyst
#66

Hello. Apologies, I've got my glasses on. First question: could you help us understand, just qualitatively or as a rough idea, what share of the products you're selling this year would count as new models or new products? If you had to put a percentage or a range on it, how much of this year's sales comes from items under 12 months old? Any comment there would be my first question. Second, an update on the U.S. with MonaLisa — where do the studies stand? When should we expect news flow on the scientific studies? My final question concerns Asclepion and the supply shortages in Q1. Are those persisting into Q2? Are they worsening at all? Some color would help. What exactly is it — chips? What are you struggling to source? Thank you.

Andrea Cangioli

executive
#67

When we talk about new products from the past 12 months — genuinely brand-new items — 12 months is a brief window, even for a company like ours that innovates strongly. Take the medical business: in hair removal, roughly 40% of what we offer there consists of products that have been on the market for under one year. Across medical as a whole, it's probably somewhere around 15%-20% of products introduced during the last year — during the last year. MonaLisa Touch — that's still under discussion. We keep getting closer and closer, and we're reviewing the contracts. The studies that need to be run in the United States haven't received the green light yet, since we still have to finalize the agreement with Cynosure. That study is very expensive, and it's tied to distribution networks — sorry, to distribution contracts. At this point it's really dragging on for a very, very long time, but we're not there yet. Our hope, and what we're counting on, is to get it closed — at least with Cynosure, we managed to sign some very significant contracts that are now delivering a significant impact. But where MLT is concerned, we're still not there yet. With Asclepion, production went better during the month of April. Sorry — things got worse in the month of April, but they've now improved again. What we're talking about here is electrical components that form part of their power supply — that was the main issue — along with a hydraulic component that forms part of the chilling unit.

Andrea Cangioli

executive
#68

What's remarkable, Emmanuel, is that these shortages strike the most varied components. We've seen shortages involving microchips, and also with standard semiconductors, diodes. Shortages have hit fans. Shortages have hit cooling fluids. Shortages have hit parts for cooling devices. It's, I mean, we're being hit from every direction, and we have to endure every kind of effort.

Analyst

analyst
#69

That’s great. Thanks so much.

Bianca Fersini-Mastelloni

executive
#70

Andrea — Andrea, there's one more question coming in from Manon Coulon at Erasmus Gestion. Go ahead, Manon.

Manon Coulon

analyst
#71

Hello, and thanks for taking my question. I just have one, please. It concerns the price increases you touched on a bit in your prepared remarks. Could you give us a sense of how Q1 broke down between volume and price mix? And perhaps the price increases you expect to put through for the remainder of the year? Thanks.

Andrea Cangioli

executive
#72

Apologies. We don't actually track that figure even within our own product lineup. Roughly 140 products are sold by us, and each of those comes in multiple versions. Price increases are something we implement. We lack any precise monitoring of how prices shift. Regrettably, details of that kind aren't something I can provide. What I can share, however, is that our prices are being raised gradually so we can offset a cost rise that we consider—as I noted—to be near 7% by the close of the second quarter, with likely additional increases continuing through the year.

Manon Coulon

analyst
#73

Appreciate that.

Bianca Fersini-Mastelloni

executive
#74

Is there anything else? All right, since no further questions have come in, we'll bring this conference to a close. Our thanks go to Andrea Cangioli and to Enrico Romagnoli, and thanks as well to every investor who joined this conference — we look forward to having all of you with us at the next event. Good afternoon, everyone.

Andrea Cangioli

executive
#75

So long, everyone.

Bianca Fersini-Mastelloni

executive
#76

Bye. Bye.

Andrea Cangioli

executive
#77

I'm hoping as many of you as possible will be here in Florence on May 31st — ideally most of you. It would be great if at least a few of you can attend. Thanks for joining us today, and I hope we'll see you in Florence.

Enrico Romagnoli

executive
#78

Thanks.

Bianca Fersini-Mastelloni

executive
#79

Take care.

Analyst

analyst
#80

Appreciate it. Goodbye.

Enrico Romagnoli

executive
#81

Thanks, everyone. Goodbye.

Andrea Cangioli

executive
#82

Take care.

Bianca Fersini-Mastelloni

executive
#83

Take care. So long, Nicola, and thanks a lot.

Enrico Romagnoli

executive
#84

Thanks, everyone. Bye.

Bianca Fersini-Mastelloni

executive
#85

Thanks to each of you. Yeah. Take care.

Analyst

analyst
#86

Thanks. Goodbye.

Bianca Fersini-Mastelloni

executive
#87

Thanks, everyone. Goodbye.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete EL.En. S.p.A. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to EL.En. S.p.A. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in EL.En. S.p.A. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.